Cytarabine induces cachexia with lipid malabsorption via zippering the junctions of lacteal in murine small intestine

‍Park, Mi-Rae; Lee, Hye-Jin; Kim, Nam Hoon; Lee, Jung Hoon; Jeong, Yong Taek; Kim, Inho; Choi, Sang-Hyun; Seo, Kwan Sik; Kim, Dong-Hoon

doi:10.1016/j.jlr.2023.100387

Cited by 3 publications

(1 citation statement)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Glutamine release from skeletal muscle escalates during proteolysis [21] but cytarabine metabolism also generates significant ammonia via deamination [22] that may necessitate more Glul as an adaptive stress response. As muscle mass declines, cytarabine-generated ammonia load may overwhelm adaptive Glul overexpression and either drive, or be symptomatic of, muscle wasting.…”

Section: Discussionmentioning

confidence: 99%

Haptoglobin and glutamine synthetase may biomark cachexia induced by anti-acute myeloid leukemia chemotherapy

Campelj,

Timpani,

Spiesberger

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Anti-cancer chemotherapy is an underappreciated contributor to cancer cachexia, an often irreversible body wasting condition that causes 20-30% of cancer-related deaths. An obstacle to predicting, monitoring and understanding the mechanisms underlying chemotherapy cachexia is that each cancer (and sub-type) is assigned different chemotherapeutic compounds, typically in multi-agent regimens. Here, we investigate the chemotherapy induction regimen (CIR) used in haematological cancer, acute myeloid leukemia (AML). We hypothesized that the AML CIR would induce cachexia, including loss of lean tissue mass and skeletal muscle atrophy. Methods: Using an unbiased proteomics approach we interrogated the underlying molecular mechanisms. 3-month-old male Balb/c mice were treated with the AML CIR via intraperitoneal injections of daunorubicin (1.7 mg/kg) on days 1-3, and cytarabine (33.2 mg/kg) administered on days 1-7 or vehicle. Mice were assessed 24 hours after the last treatment, on day 8, or allowed to recover for 2 weeks and assessed on day 22. A third cohort were given access to running wheels in cages. We assessed body composition, whole body metabolism and assessed the muscle proteome using quantitative tandem mass tag labelling LC-MS/MS analysis. Results: The AML CIR induced acute cachexia involving a ~13% loss of body mass, ~9% loss of lean mass and ~10% reduction in skeletal muscle fibre size. Whole body metabolism and ambulatory activity declined. This cachexic phenotype did not recover over the 2-week post-CIR period (lean mass loss post-CIR: 1-week ~7% vs 2-weeks ~9%). In voluntarily active CIR-treated mice, body wasting was exacerbated due to unchecked loss of fat mass (CIR sedentary: ~31% vs CIR active: ~51%). Muscle proteome studies revealed upregulation of haptoglobin (Hp) and glutamine synthetase (Glul), which were positively correlated with body and lean mass loss. Hp was sensitive to the conditional induction, recovery and exacerbation of AML CIR-mediated cachexia, suggestive of biomarker potential. Conclusions: The AML CIR induces an acute reduction of body, lean and fat mass underpinned by skeletal muscle atrophy, hypermetabolism and catabolism. Our data uncovered a conditionally sensitive muscle biomarker in Hp, which may be useful as a prognostic tool across other scenarios of chemotherapy-induced myopathy and cachexia or as a target for therapeutic discovery in follow up studies.

show abstract

Section: Discussionmentioning

confidence: 99%